Inclusion Criteria:  Adult male or female patients Histological confirmed diagnosis of advanced/metastatic solid tumor type. Patients previously, currently or to be treated with Larotrectinib within the ATU/post-ATU period. Patient must be > 25 years-old at time of larotrectinib start. Patients not opposed to collection of personal clinical data